Rocket Pharmaceuticals, Inc. filings document regulatory, financial, governance, and capital-structure disclosures for a biotechnology company developing and commercializing genetic therapies for rare disorders. Recent 8-K reports cover quarterly and annual operating results, FDA-related events for KRESLADI, Priority Review Voucher monetization, and clinical-program updates for cardiovascular gene therapy candidates.
The filing record also includes definitive proxy materials for annual-meeting governance matters and material-agreement disclosures related to an at-the-market common stock offering program under a shelf registration statement. These documents describe board and shareholder-vote matters, equity financing mechanics, common stock structure, business risks, and formal disclosure controls around product approvals and development programs.
An affiliate of RCKT filed a Rule 144 notice to sell 12,279 shares of common stock through Fidelity Brokerage Services, with an aggregate market value of $40,669.28. The shares were acquired via restricted stock vesting on 02/11/2026 and the approximate sale date is 02/13/2026.
The notice states that 108,222,228 shares of the issuer’s common stock were outstanding. Over the prior three months, the same seller disposed of 6,276 shares of common stock for gross proceeds of $18,720.05. The filer represents they are not aware of undisclosed material adverse information about the issuer.
Rocket Pharmaceuticals shareholder Jonathan D. Schwartz has filed to sell 14,508 shares of common stock. The planned sale, through Fidelity Brokerage Services, has an aggregate market value of $48,051.95, with an approximate sale date of February 13, 2026 on NASDAQ.
The 14,508 shares were acquired on February 11, 2026 via restricted stock vesting from the issuer as compensation. Schwartz previously sold 2,545 common shares on November 18, 2025 for gross proceeds of $7,591.22. Shares outstanding were 108,222,228 at the time referenced.
John Militello filed a notice of proposed sale of 3,726 shares of common stock of issuer RCKT under Rule 144. The shares, with an aggregate market value of $12,340.88, are to be sold through Fidelity Brokerage Services LLC on NASDAQ, where 108,222,228 shares are outstanding.
The securities were acquired on 02/11/2026 through restricted stock vesting from the issuer as compensation. Militello previously sold 1,086 common shares for gross proceeds of $3,239.32 on 11/18/2025. By signing, he represents he is not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
The Vanguard Group filed an amended Schedule 13G reporting beneficial ownership of 8,544,423 shares of Rocket Pharmaceuticals common stock, representing 7.89% of the outstanding class.
Vanguard reports no sole voting or dispositive power, only shared authority over these shares, which are held for clients. It states the position is held in the ordinary course of business, not to change or influence control of Rocket Pharmaceuticals. Vanguard also notes an internal realignment, after which certain subsidiaries may report beneficial ownership separately while continuing the same investment strategies.
Rocket Pharmaceuticals director Elisabeth Bjork reported buying 10,000 shares of common stock on January 2, 2026 at $3.44 per share. After this purchase, she beneficially owned 50,000 shares in total.
The total includes 30,000 restricted stock units that convert into common stock on a one-for-one basis and are scheduled to vest in full on June 18, 2026. The filing indicates the shares are held directly rather than through another entity.
Rocket Pharmaceuticals insider trading update: A company officer reported a small sale of common stock. On 11/18/2025, the Chief Science & Gene Therapy Officer disposed of 2,545 shares of Rocket Pharmaceuticals, Inc. (RCKT) common stock at a price of $2.983 per share in an open market sale. After this transaction, the reporting person beneficially owns 299,064 shares, which include Restricted Stock Units that convert into common stock on a one-for-one basis.
Rocket Pharmaceuticals, Inc. (RCKT) CEO and director Gaurav Shah reported an open-market sale of 6,276 shares of common stock on November 18, 2025 at a price of $2.983 per share.
Following this transaction, he beneficially owns 778,296 shares directly, 207,897 shares indirectly through his spouse, and 198,341 shares indirectly through the Gaurav D. Shah Irrevocable Trust. The reported holdings include Restricted Stock Units that convert into common stock on a one-for-one basis.
Rocket Pharmaceuticals, Inc. (RCKT) officer John Militello reported a sale of 1,086 shares of common stock on November 18, 2025 at a price of $2.983 per share. After this transaction, he beneficially owns 65,920 shares, held directly. The holdings include restricted stock units (RSUs) that convert to common stock on a one-for-one basis. Militello is identified as Vice President of Finance, Treasurer and Principal Accounting Officer.
Rocket Pharmaceuticals, Inc. (RCKT) reported an insider stock transaction by its General Counsel, Martin Louis Wilson. On 11/18/2025, he sold 1,646 shares of Rocket Pharmaceuticals common stock at a price of $2.983 per share in a single transaction. After this sale, he beneficially owns 383,816 shares of Rocket Pharmaceuticals common stock in direct ownership. These holdings include Restricted Stock Units that convert to common stock on a one-for-one basis.
Rocket Pharmaceuticals (RCKT) reported an insider equity award. The company’s General Counsel acquired 100,000 shares on 11/03/2025 at a reported price of $0, identified as Restricted Stock Units that convert to common stock on a one-for-one basis and fully vest on 11/03/2026.
Following this transaction, the reporting person beneficially owned 385,462 shares, held directly. This filing reflects routine equity compensation rather than an open‑market purchase.